House of medicine

Poor Prognostic Markers in Rheumatoid Arthritis High anti-CCP titre High RF titre High CRP / ESR Persistent high disease activity Early radiographic erosions Smoking Extra-articular manifestations Most specific prognostic antibody: Anti-CCP Best evidence of established structural damage: Radiographic erosions

🩺 VASOPRESSIN IN SEPTIC SHOCK — HIGH-YIELD 🔹 Norepinephrine remains FIRST-LINE vasopressor in septic shock. 🔹 If MAP remains inadequate or norepinephrine requirements are progressively increasing: ➡️ Add vasopressin rather than simply escalating norepinephrine indefinitely. 💉 Why Vasopressin? • Acts mainly on V1a receptors • → Vasoconstriction • → ↑ SVR • → ↑ MAP • Works through a non-adrenergic pathway 📌 Typical Dose • Vasopressin: 0.03 units/min IV infusion • Usually administered as a fixed-dose infusion • Unlike norepinephrine, it is generally not aggressively titrated 🎯 Benefits • Catecholamine-sparing effect • ↓ Norepinephrine requirements • Provides an alternative vasoconstrictor pathway • Helps restore vascular tone and achieve target MAP • May limit excessive catecholamine exposure ⚠️ Important Risks Excessive vasoconstriction may cause: • 🖐️ Digital/limb ischemia • 🩸 Mesenteric ischemia • ❤️ Myocardial ischemia • Other ischemic complications ➡️ Higher doses = greater risk of ischemia. 🚨 Postgraduate Pearl Vasopressin treats vasoplegia — NOT the underlying cause of septic shock. Always address: • 💧 Fluid status/resuscitation • 💊 Appropriate antibiotics • 🔍 Rapid source control • ❤️ Cardiac function • 🩸 Other causes of persistent hypotension 🧠 Remember Septic shock + increasing norepinephrine requirement ➡️ Norepinephrine + Vasopressin ❌ Not: endlessly escalating catecholamines Vasopressin = non-adrenergic vasoconstriction + catecholamine sparing.

HOW TO READ #BRAIN_CT STEP BY STEP #CTHead #CTBrain #CTScan #trending #viral #explorepage

D-dimer = helps rule out PE, not rule it in. D-dimer is sensitive but nonspecific.

📚 #CMV CYTOMEGALOVIRUS Treatment Protocol (Theory Only): First-Line Treatment: * Mild to Moderate: Valganciclovir 900 mg PO BD (dose adjust for GFR). * Severe/Life-Threatening/GI Malabsorption: Ganciclovir 5 mg/kg IV q12h (dose adjust for GFR). Second-Line Treatment: * For resistanceto valganciclovir or ganciclovir: ➡️ Foscarnet. Monitoring: * Check plasma CMV DNA weekly. * Do not change antiviral therapy in first few weeks if clinically improving despite DNA persistence/increase. * Reduce dose only if GFR worsens as underdosing increases the risk of treatment failure and antiviral resistance. * For leukopenia: Consider G-CSF, withhold myelosuppressive drugs, then consider antiviral change. Duration: * Minimum 2 weeks until clinical resolution and CMV DNAemia clearance (<200 IU/mL) on 1–2 consecutive weekly samples. Additional: * In patients without concomitant rejection, reduction of immunosuppression may be considered in: - Severe CMV disease - Poor clinical response - High viral load - Cytopenia Adjunctive immunoglobulin therapy is not routinely recommended. Secondary CMV prophylaxis is not routinely recommended. Suspect ganciclovir resistance if: - Prior cumulative exposure to valganciclovir/ganciclovir is >6 weeks, and - There is clinical treatment failure after 2 weeks of therapy or persistent CMV DNAemia during prophylaxis. #MNA #MedicineNotesAcademy #Nephrology #CMV #KidneyTransplant #ExamPearls #WhatsAppAcademy

7 Knee Conditions You Must Know For USMLE 1️⃣ ACL Tear 🔬 Non-contact pivot or valgus blow (the tibia slides forward) 📋 Pop + rapid swelling (hemarthrosis) + giving way 🔎 Anterior drawer / Lachman. LAMP = Lateral condyle to Anterior tibia 2️⃣ PCL Tear 🔬 Dashboard injury or a fall onto a bent knee 🔎 Posterior drawer (the tibia sags back) 3️⃣ Collateral Ligaments (MCL and LCL) 🔬 Valgus blow tears the MCL; varus blow tears the LCL 🔎 Valgus stress opens the medial side = MCL; varus opens the lateral = LCL ⚠️ The MCL is attached to the medial meniscus (they tear together) 4️⃣ Meniscal Tear 🔬 Twist on a planted foot; the medial meniscus is most common 📋 Joint-line tenderness + locking + effusion 🔎 McMurray. LIME = Lateral tears on Internal rotation, Medial on External 5️⃣ Unhappy Triad 🔬 Valgus blow to a planted foot -> ACL + MCL + meniscus ⚠️ Classically the medial meniscus, but the lateral is now more common 6️⃣ Prepatellar Bursitis 🔬 Repeated kneeling (housemaid's knee) 📋 Swollen, tender lump over the front of the kneecap 7️⃣ Baker (Popliteal) Cyst 🔬 Fluid in the bursa behind the knee; linked to OA and RA ⚠️ Rupture mimics a DVT (calf pain and swelling) Comment "NOTES" to get access to my USMLE 2026 Step 1, 2 & 3 notes #usmle #medstudent #medschool #medicalstudent #medicalschool

This does not mean the patient has failed. It means treatment must evolve. Therapy may progress from: 🥗 Lifestyle intervention ➡️ Metformin ➡️ Second medication ➡️ Third medication ➡️ Basal insulin ➡️ Prandial or combination insulin therapy Regular reassessment helps prevent years of uncontrolled hyperglycaemia. ━━━━━━━━━━━━━━━━━━ 🩺 19. MONITORING AND FOLLOW-UP ━━━━━━━━━━━━━━━━━━ Patients should be monitored for: 🩸 A1C 🫘 Kidney function 🧪 Electrolytes 🩺 Blood pressure ⚖️ Weight 🧫 Albuminuria 👁️ Retinopathy 🦶 Neuropathy and foot disease ❤️ Cardiovascular risk 💊 Medication side effects 🧠 Depression and diabetes distress A1C is commonly reassessed every three months when therapy is changing or glucose is above target, and less frequently once stable. ━━━━━━━━━━━━━━━━━━ 🌟 KEY MESSAGE ━━━━━━━━━━━━━━━━━━ The best diabetes medication is not the same for every patient. Treatment should be: ✅ Individualised ✅ Timely ✅ Cardiovascularly protective ✅ Kidney protective ✅ Weight conscious ✅ Affordable ✅ Safe ✅ Acceptable to the patient The ultimate goal is not only a lower A1C. It is to help patients live longer, healthier lives with fewer cardiovascular, kidney, neurological and eye complications. 📌 Educational content only. Treatment decisions should be individualised by a qualified healthcare professional. ❤️ Follow Cardiovascular Education for more evidence-based medical learning. #Type2Diabetes #DiabetesManagement #Metformin #GLP1 #SGLT2 #Insulin #CardiovascularDisease #HeartFailure #KidneyDisease #ASCVD #MedicalEducation #CardiovascularEducation #A1C #WeightManagement #DiabetesCare

In advanced nondialysis CKD, particularly eGFR <30 mL/min/1.73 m², treatment options may include: 💉 Insulin 💊 Linagliptin 💉 Carefully titrated GLP-1–based therapy 💊 Repaglinide 💊 Low-dose short-acting sulfonylurea, such as glipizide Important considerations: ⚠️ Hypoglycaemia risk increases in advanced CKD ⚠️ Insulin requirements may decrease ⚠️ GLP-1 gastrointestinal effects may cause dehydration ✅ Linagliptin does not generally require renal dose adjustment ━━━━━━━━━━━━━━━━━━ ⚖️ 13. OBESITY OR OBESITY-RELATED COMORBIDITY ━━━━━━━━━━━━━━━━━━ When substantial weight reduction is a primary treatment goal, GLP-1–based therapy may be considered early. High-potency options include: 🥇 Tirzepatide 🥈 Subcutaneous semaglutide These therapies can provide: ✅ Significant weight loss ✅ Strong A1C reduction ✅ Cardiovascular benefit with selected agents ✅ Kidney protection with selected agents Cost, insurance coverage, tolerability and contraindications must be considered. ━━━━━━━━━━━━━━━━━━ 🚨 14. A1C >9% OR SYMPTOMATIC HYPERGLYCAEMIA ━━━━━━━━━━━━━━━━━━ When A1C is markedly elevated or the patient has: 🚽 Polyuria 🥤 Polydipsia ⚖️ Unintentional weight loss 😴 Significant fatigue 🔥 Catabolic symptoms Treatment should be intensified promptly. Preferred options include: 💉 Insulin or 💉 GLP-1–based therapy if type 1 diabetes is unlikely and the patient is not catabolic Insulin is preferred when there is insulin deficiency, severe hyperglycaemia or catabolism. Basal insulin options include: 💉 NPH 💉 Insulin glargine 💉 Insulin degludec Continuing metformin with insulin, when safe, may reduce insulin requirements and limit weight gain. ━━━━━━━━━━━━━━━━━━ ➕ 15. WHEN TO ADD A SECOND AGENT ━━━━━━━━━━━━━━━━━━ A second medication is usually added when A1C remains above the individualised target after approximately three months of metformin plus lifestyle intervention. Before intensifying therapy, review: 🔍 Medication adherence 🔍 Diet and physical activity 🔍 Weight gain 🔍 Intercurrent illness 🔍 Glucocorticoid use 🔍 Atypical antipsychotics 🔍 Immunosuppressive therapy 🔍 Possible latent autoimmune diabetes in adults 🔍 Therapeutic inertia Treatment failure is not always medication failure. The underlying cause should be identified first. ━━━━━━━━━━━━━━━━━━ 🧬 16. CHOOSING THE SECOND AGENT ━━━━━━━━━━━━━━━━━━ The best medication depends on the individual patient. Consider: ✅ ASCVD ✅ Heart failure ✅ Kidney disease ✅ Obesity ✅ A1C reduction needed ✅ Hypoglycaemia risk ✅ Weight effects ✅ Side effects ✅ Cost and access ✅ Patient preference Potential options include: 💉 GLP-1–based therapy 💊 SGLT2 inhibitor 💉 Basal insulin 💊 DPP-4 inhibitor 💊 Short-acting sulfonylurea 💊 Repaglinide 💊 Pioglitazone ━━━━━━━━━━━━━━━━━━ 📊 17. COMPARING COMMON DRUG CLASSES ━━━━━━━━━━━━━━━━━━ 💉 GLP-1–based therapy ✅ Strong A1C reduction ✅ Weight loss ✅ Low hypoglycaemia risk ✅ Cardiovascular and kidney benefit with selected agents ⚠️ Gastrointestinal effects ⚠️ Cost and access concerns 💊 SGLT2 inhibitors ✅ Heart-failure and kidney protection ✅ Weight loss ✅ Low hypoglycaemia risk ⚠️ Genital infections ⚠️ Volume depletion ⚠️ Ketoacidosis risk ⚠️ Weaker glycaemic effect at low eGFR 💉 Basal insulin ✅ Powerful glucose lowering ✅ Effective at any A1C ⚠️ Hypoglycaemia ⚠️ Weight gain ⚠️ Requires education and titration 💊 Sulfonylureas ✅ Effective ✅ Inexpensive ⚠️ Hypoglycaemia ⚠️ Weight gain ➡️ Short-acting agents are generally preferred 💊 DPP-4 inhibitors ✅ Well tolerated ✅ Weight neutral ✅ Low hypoglycaemia risk ⚠️ Modest glucose-lowering effect 💊 Pioglitazone ✅ Improves insulin sensitivity ✅ Low hypoglycaemia risk ⚠️ Weight gain ⚠️ Fluid retention ⚠️ Heart-failure risk ⚠️ Fracture risk ━━━━━━━━━━━━━━━━━━ 📈 18. DIABETES IS PROGRESSIVE ━━━━━━━━━━━━━━━━━━ Even after an initially successful response, glucose levels may rise over time because of progressive beta-cell dysfunction and insulin resistance.

Diabetes distress and depression can significantly interfere with self-care. Patients may feel overwhelmed by: 💊 Multiple medications 🩸 Glucose monitoring 🍽️ Dietary restrictions 🏃 Exercise expectations ⚠️ Fear of complications Psychological support and psychotherapy may improve both emotional wellbeing and glucose control. Mental health is part of diabetes care. ━━━━━━━━━━━━━━━━━━ 💊 7. WHEN SHOULD MEDICATION BE STARTED? ━━━━━━━━━━━━━━━━━━ For most patients with A1C clearly above target—approximately >7.5–8%—medication should usually begin at diagnosis together with lifestyle intervention. For highly motivated patients with A1C close to target, a supervised lifestyle trial may be considered: ⏳ Approximately three months if modifiable dietary contributors are present ⏳ Three to six months in selected patients with A1C near target Treatment should not be delayed when hyperglycaemia is significant or symptoms are present. ━━━━━━━━━━━━━━━━━━ 💙 8. METFORMIN: COMMON FIRST-LINE THERAPY ━━━━━━━━━━━━━━━━━━ In the absence of contraindications or a strong indication for another medication class, metformin remains a commonly preferred initial therapy. A practical initiation strategy: 💊 Start 500 mg once daily with the evening meal 💊 Add 500 mg with breakfast if tolerated 💊 Increase gradually every one to two weeks 💊 Usual maximum total dose: approximately 2000 mg/day Advantages: ✅ Effective glucose lowering ✅ Very low hypoglycaemia risk ✅ Usually weight neutral or modest weight loss ✅ Low cost ✅ Extensive clinical experience For gastrointestinal intolerance: ✔️ Take with food ✔️ Titrate more slowly ✔️ Consider extended-release metformin ━━━━━━━━━━━━━━━━━━ ❤️ 9. WHEN ANOTHER DRUG CLASS MAY BE PREFERRED ━━━━━━━━━━━━━━━━━━ Medication choice should be guided by comorbidities—not only by A1C. 🫀 Established ASCVD or high cardiovascular risk Consider a GLP-1–based therapy with proven cardiovascular benefit, such as: 💉 Dulaglutide 💉 Liraglutide 💉 Semaglutide 💉 Tirzepatide SGLT2 inhibitors with cardiovascular benefit may also be appropriate: 💊 Empagliflozin 💊 Dapagliflozin 💊 Canagliflozin GLP-1–based therapy is particularly attractive when: ✅ Weight loss is desired ✅ A1C reduction is a major priority ✅ ASCVD predominates ━━━━━━━━━━━━━━━━━━ 💚 10. HEART FAILURE OR DIABETIC KIDNEY DISEASE ━━━━━━━━━━━━━━━━━━ When heart failure or diabetic kidney disease predominates, an SGLT2 inhibitor is generally prioritised because of proven cardiorenal protection. Examples include: 💊 Empagliflozin 10 mg 💊 Dapagliflozin 10 mg 💊 Canagliflozin 100 mg Potential benefits: ✅ Reduced heart-failure hospitalisation ✅ Slower kidney disease progression ✅ Reduced cardiovascular risk ✅ Reduced mortality in selected populations Important points: ⚠️ Glucose-lowering efficacy declines as eGFR falls ✅ Heart and kidney protection may continue even when glycaemic efficacy is reduced 💊 Additional glucose-lowering medication may still be required GLP-1–based therapy may also provide kidney protection and remains effective for glucose lowering across a wider range of kidney function. ━━━━━━━━━━━━━━━━━━ ⚠️ 11. SGLT2 INHIBITOR PRECAUTIONS ━━━━━━━━━━━━━━━━━━ Use caution or avoid in selected patients with: ❌ Recurrent genital yeast infections ❌ Frequent urinary infections ❌ Active foot ulceration ❌ High risk of diabetic ketoacidosis ❌ Severe dehydration risk ❌ Significant alcohol or substance misuse ❌ Conditions causing pancreatic insulin deficiency SGLT2 inhibitors should generally be held: ⏸️ Three to four days before surgery ⏸️ Before colonoscopy preparation ⏸️ During prolonged fasting ⏸️ During poor oral intake or acute illness This helps reduce the risk of euglycaemic diabetic ketoacidosis. ━━━━━━━━━━━━━━━━━━ 🫘 12. ADVANCED CHRONIC KIDNEY DISEASE ━━━━━━━━━━━━━━━━━━

🩺 PRACTICE CHANGING UPDATES 2026 TYPE 2 DIABETES: A PRACTICAL GUIDE TO GLUCOSE-LOWERING THERAPY 📚 From lifestyle modification to metformin, GLP-1 therapy, SGLT2 inhibitors and insulin intensification Type 2 diabetes management is not only about lowering blood glucose. Effective treatment should also reduce cardiovascular risk, protect kidney function, support weight management, prevent complications and improve quality of life. ━━━━━━━━━━━━━━━━━━ 🎯 1. INDIVIDUALISE THE TREATMENT GOAL ━━━━━━━━━━━━━━━━━━ For most nonpregnant adults: 🔴 Target A1C: <7% However, the goal should be individualised according to: ✅ Age ✅ Life expectancy ✅ Comorbidities ✅ Duration of diabetes ✅ Risk of hypoglycaemia ✅ Medication burden ✅ Patient preferences and treatment cost Older adults, people with multiple comorbidities or those with limited life expectancy may need less intensive targets. Common glucose targets include: 🩸 Fasting glucose: 80–130 mg/dL 🩸 Post-meal glucose: <180 mg/dL, measured approximately 90–120 minutes after eating Lowering A1C reduces the risk of microvascular complications such as: 👁️ Retinopathy 🫘 Kidney disease 🦶 Neuropathy However, very aggressive glucose lowering may increase hypoglycaemia, adverse effects and polypharmacy. The goal is safe and sustainable control—not simply the lowest possible A1C. ━━━━━━━━━━━━━━━━━━ ❤️ 2. CARDIOVASCULAR RISK REDUCTION IS ESSENTIAL ━━━━━━━━━━━━━━━━━━ Every patient with type 2 diabetes should receive comprehensive cardiovascular risk management. This includes: 🚭 Smoking cessation 🩺 Blood pressure control 💊 Statin therapy when indicated 🥗 Healthy nutrition 🏃 Regular physical activity ⚖️ Weight reduction or maintenance 💊 Antiplatelet therapy for established ASCVD when appropriate Managing glucose alone is not enough. Blood pressure, cholesterol, weight, smoking and kidney health must also be addressed. ━━━━━━━━━━━━━━━━━━ 📘 3. DIABETES EDUCATION ━━━━━━━━━━━━━━━━━━ Patients should participate in structured diabetes self-management education and support. Education should cover: ✅ Nutrition ✅ Exercise ✅ Medication adherence ✅ Glucose monitoring ✅ Prevention of hypoglycaemia ✅ Foot care ✅ Recognition of complications ✅ Sick-day management ✅ Emotional and psychological support Diabetes education, including mobile-based interventions, can meaningfully improve A1C. ━━━━━━━━━━━━━━━━━━ 🥗 4. NUTRITION AND WEIGHT MANAGEMENT ━━━━━━━━━━━━━━━━━━ Weight management should be considered a major therapeutic goal alongside glucose control. Even modest weight loss can improve: ✅ Insulin resistance ✅ Glycaemic control ✅ Blood pressure ✅ Fatty liver disease ✅ Sleep apnoea ✅ Mobility and quality of life A body-weight reduction of approximately 5–10% can provide important metabolic benefits. Patients should be encouraged to: 🥦 Choose nutrient-dense foods 🥤 Avoid sugar-sweetened drinks 🧃 Limit fruit juices 🍽️ Maintain consistent carbohydrate intake 🥗 Increase vegetables, fibre and lean protein 📉 Reduce excessive calorie intake ⚖️ Aim for weight loss or at least prevention of further weight gain The most successful programmes combine nutrition, physical activity and behavioural support. ━━━━━━━━━━━━━━━━━━ 🏃 5. EXERCISE RECOMMENDATIONS ━━━━━━━━━━━━━━━━━━ Exercise improves insulin sensitivity even without significant weight loss. Recommended activity: 🚶 At least 150 minutes/week of moderate-intensity aerobic exercise 📅 Spread over at least three days ⏳ Avoid more than two consecutive inactive days 🏋️ Resistance training at least twice weekly, when safe 🪑 Reduce prolonged sitting and sedentary time People with advanced retinopathy, severe coronary disease or other exercise-limiting conditions should receive individualised recommendations. ━━━━━━━━━━━━━━━━━━ 🧠 6. PSYCHOLOGICAL HEALTH ━━━━━━━━━━━━━━━━━━

📌دول 20 Drug interaction مهمين جدا 1️⃣ SSRIs + Tramadol = Serotonin Syndrome + Seizures. 2️⃣ Fluvoxamine + Tizanidine = Severe hypotension و CNS depression. 3️⃣ Clarithromycin + Apixaban/Rivaroxaban = Major bleeding. 4️⃣ NSAIDs + ACEI/ARB + Diuretics = Triple Whammy و Acute Kidney Injury. 5️⃣ TMP-SMX + ACEI/ARB/Spironolactone = Life threatening hyperkalemia. 6️⃣ PPIs + Methotrexate (high doses) = Toxicity 7️⃣ Fluoroquinolones + Corticosteroids = Tendon rupture. 8️⃣ Linezolid + SSRIs/SNRIs = Serotonin Syndrome. 9️⃣ Amiodarone + DOACs = Increased bleeding risk. 🔟 Fluconazole + Sulfonylureas = Severe hypoglycemia. 1️⃣1️⃣ Verapamil/Diltiazem + Beta blockers = Severe bradycardia and heart block. 1️⃣2️⃣ Levothyroxine + Iron/Calcium = Treatment failure. 1️⃣3️⃣ Sildenafil + Nitrates = Catastrophic hypotension. 1️⃣4️⃣ Spironolactone + Potassium supplements = Severe hyperkalemia. 1️⃣5️⃣ Macrolides + Statins = Rhabdomyolysis. 1️⃣6️⃣ NSAIDs + Lithium = Lithium toxicity. 1️⃣7️⃣ Carbamazepine + DOACs = Treatment failure بسبب الـ CYP3A4 induction. 1️⃣8️⃣ Rifampicin + Oral contraceptives = Contraceptive failure. 1️⃣9️⃣ Metronidazole + Warfarin = Markedly elevated INR. 2️⃣0️⃣ Colchicine + Clarithromycin = Fatal toxicity خصوصا فى كبار السن ومرضى الكلى. #𝓜𝓪𝓱𝓶𝓸𝓾𝓭_𝓢𝓱𝓪𝓭𝔂

#Ventricular fibrillation is characterized by: Regularity: Chaotic rhythm Rate: Unable to determine P Wave: Unable to determine PR Interval: Unable to determine QRS Complex: Unable to determine #ECG #CARDIOLOGY@HouseOfmedicinee

#Polymorphic ventricular tachycardia is characterized by: - Regularity: Usually irregular - Rate: Atrial rate not measurable; ventricular rate 150-250 bpm - P Wave: No P waves - PR Interval: No PRI - QRS Complex: Variable morphology with asymmetrical - QRS complexes; wide and bizarre – usually > 0.12 seconds #ECG #CARDIOLOGY@HouseOfmedicinee

#Asystole is characterized by: - Regularity: None - Rate: None - P Wave: Flat line - PR Interval: None - QRS Complex: Flat line #ECG #CARDIOLOGY @HouseOfmedicinee